Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Zasocitinib is an inhibitor of tyrosine kinase 2 (TYK2).1 It selectively binds to the TYK2 Janus homology (JH2) domain (Kd = 0.0038 nM) over the JAK1 and JAK2 JH2 domains (Kds = 4,975 and 23,000 nM, respectively). Zasocitinib inhibits the production of chemokine (C-X-C motif) ligand 10 (CXCL10) induced by IFN-α in isolated human, mouse, and rat whole blood (IC50s = 22, 347, and 91 nM, respectively). It also Inhibits IL-23-induced STAT3 phosphorylation in human CD161+CD3+ Th17 cells (IC50 = 3.7 nM). Zasocitinib (3, 10, and 30 mg/kg twice per day) decreases ankle diameter in a rat model of adjuvant-induced arthritis. It reduces the colon weight-to-length ratio and improves histology scores in a mouse model of colitis induced by an anti-CD40 antibody when administered at doses of 30 and 90 mg/kg.
WARNING This product is not for human or veterinary use.
1. Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-